From: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience
Variables | Survival time, months | P univariate | P multivariate | Odds ratio* (95 % CI) |
---|---|---|---|---|
Gender | ||||
Male | 24.8 ± 18.6 | |||
Female | 29.4 ± 17.4 | 0.202 | ||
Age, y | ||||
≤ 60 | 26.5 ± 19.4 | |||
> 60 | 25.6 ± 17.1 | 0.759 | ||
Tumor marker | ||||
Normal | 26.7 ± 18.1 | |||
Abnormal | 23.9 ± 19.2 | 0.479 | ||
NLR | ||||
≤ 2.8 | 27.2 ± 18.4 | |||
> 2.8 | 24.1 ± 18.7 | 0.340 | ||
Chemotherapy | ||||
Yes | 26.4 ± 18.6 | |||
N0 | 24.0 ± 16.9 | 0.576 | ||
Types of surgery | ||||
Endoscopic | 66.0 ± 5.7 | |||
Open/Laparoscopic | 41.7 ± 3.4 | 0.001 | 0.580 | 0.6 (0.1 ~ 4.2) |
Depth of invasion | ||||
T1/T2 | 34.2 ± 19.5 | |||
T3/T4 | 20.8 ± 15.5 | <0.001 | 0.066 | 2.6 (0.9 ~ 7.2) |
Lymph node metastasis | ||||
N0 | 34.4 ± 20.4 | |||
N1 | 21.8 ± 15.6 | <0.001 | 0.277 | 0.3 (0.0 ~ 2.5) |
Number of positive LN | ||||
≤ 4 | 31.8 ± 20.5 | |||
> 4 | 19.9 ± 13.2 | <0.001 | 0.795 | 0.9 (0.4 ~ 2.0) |
Distant metastasis | ||||
M0 | 27.2 ± 18.4 | |||
M1 | 12.9 ± 11.6 | 0.012 | 0.497 | 1.4 (0.5 ~ 4.1) |
TNM stage | ||||
I/II | 35.0 ± 20.4 | |||
III/IV | 21.5 ± 15.3 | <0.001 | 0.248 | 3.9 (0.4 ~ 38.5) |
Lesions diameter | ||||
≤ 4 cm | 30.7 ± 19.2 | |||
> 4 cm | 20.1 ± 15.3 | 0.001 | 0.730 | 1.1 (0.5 ~ 2.4) |
Co-morbidity* | ||||
Absent | 27.9 ± 18.3 | |||
Present | 19.7 ± 17.0 | 0.030 | 0.060 | 2.0 (0.9 ~ 4.1) |
Surgical margin | ||||
R0 | 28.6 ± 18.5 | |||
R1/R2 | 12.6 ± 9.3 | <0.001 | 0.002 | 3.9 (1.6 ~ 9.1) |
WHO classification | ||||
NET G1/G2 | 35.6 ± 197 | |||
NET G3/MANEC | 21.2 ± 15.5 | <0.001 | 0.021 | 5.4 (1.3 ~ 22.9) |